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The in vivo efficacy of voriconazole against 4 clinical Aspergillus fumigatus isolates with MICs ranging from
0.125 to 2 mg/liter (CLSI document M38A) was assessed in a nonneutropenic murine model of disseminated
aspergillosis. The study involved TR/L98H, M220I, and G54W mutants and a wild-type control isolate. Oral
voriconazole therapy was started 24 h after intravenous infection of mice and was given once daily for 14
consecutive days, with doses ranging from 10 to 80 mg/kg of body weight, using survival as the endpoint.
Survival for all isolates was dependent on the voriconazole dose level (R2 value of 0.5 to 0.6), but a better
relationship existed for the area under the concentration-time curve over 24 h in the steady state divided by the
MIC (AUC/MIC ratio) or the AUC for the free, unbound fraction of the drug divided by the MIC (fAUC/MIC
ratio) (R2 value of 0.95 to 0.98). The 24-h fAUC/MIC ratio showed a clear relationship to effect, with an
exposure index for amount of free drug required for 50% of maximum effectiveness (fEI50) of 11.17 at day 7.
Maximum effect was reached at values of around 80 to 100, comparable to that observed for posaconazole and
A. fumigatus. Mice infected with an isolate having a MIC of 2 mg/liter required an exposure that was inversely
correlated with the increase in MIC compared to that of the wild-type control, but due to nonlinear pharma-
cokinetics, this required only doubling of the voriconazole dose. The efficacy of voriconazole for isolates with
high MICs for other triazoles but voriconazole MICs within the wild-type population range was comparable to
that for the wild-type control. Finally, we used a grapefruit juice-free murine model of aspergillosis and
concluded that this model is appropriate to study pharmacokinetic/pharmacodynamic relationships of
voriconazole.
Aspergillus fumigatus is a ubiquitous fungus and is the most
common cause of invasive fungal infections in severely immu-
nocompromised patients. Invasive aspergillosis remains asso-
ciated with significant morbidity and mortality, but the out-
come of this disease in hematopoietic stem cell recipients has
improved significantly in recent years (22). Although improved
survival coincided with multiple changes in transplantation
practices, the introduction and use of voriconazole were inde-
pendently associated with protection from invasive aspergillo-
sis-related death (22). Voriconazole is recommended for pri-
mary therapy for most clinical manifestations of invasive
aspergillosis, including central nervous system aspergillosis
(28). However, the efficacy of voriconazole might be hampered
by the development of azole resistance in aspergilli. Several
studies have indicated that acquired resistance is an emerging
problem (20) and that in vitro resistance is associated with
treatment failure (8, 20, 23, 24, 27). Most of the recently
reported mechanisms of resistance to azoles include mutations
in the fungal mitochondrial cyp51 genes, leading to alterations
in the target enzyme 14-sterol demethylase. The identified
different mutations in the fungal cyp51A gene are associated
with distinct phenotypes in vitro. These phenotypes are com-
monly characterized by partial or complete loss of susceptibil-
ity to one or more of the mold-active azoles. For instance, a
phenotype for amino acid substitutions at glycine 54 (G54) is
expressed in vitro by resistance to itraconazole and posacon-
azole (10, 14), but the activity of voriconazole remains compa-
rable to that of isolates without cyp51A mutations. Isolates
harboring the M220I substitution are resistant to itraconazole,
while the MIC of posaconazole is elevated compared to that
for wild-type isolates. The susceptibility of M220I mutant iso-
lates to voriconazole is comparable to that of wild-type iso-
lates. (12). Another A. fumigatus resistance mechanism in-
volves an amino acid substitution in cyp51A, at codon 98, in
combination with the duplication in tandem of a 34-bp se-
quence in the cyp51A promoter (TR/L98H) (13). The pheno-
typic profile for this mechanism shows in vitro resistance to
itraconazole and reduced susceptibility to posaconazole. The
activity of voriconazole in strains with a TR/L98H mutation is
variable, ranging from susceptibility of isolates to a complete
lack of activity of voriconazole.
Given the prominent role of voriconazole in the primary
therapy of invasive aspergillosis, it is important to understand
the impact of the presence of resistance mechanisms on the
efficacy of the drug. Furthermore, it is important to investigate
the efficacy of voriconazole in those isolates that are resistant
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to other azole compounds but remain susceptible to voricon-
azole in vitro. Using a nonneutropenic murine model of dis-
seminated aspergillosis, we recently showed that the efficacy of
posaconazole was dependent on the drug exposure and MIC of
the A. fumigatus isolate (11), underscoring the hypothesis that
the presence of cyp51 mutations is clinically relevant.
The aim of our research was to investigate the pharmaco-
dynamic and pharmacokinetic properties of voriconazole
against clinical A. fumigatus isolates with cyp51A mutations and
to determine whether the efficacy of the drug was attenuated in
isolates with a mutation in the cyp51A gene but a voriconazole-
susceptible phenotype.
MATERIALS AND METHODS
Isolates. Four clinical A. fumigatus isolates were used in this study. Clinical
isolates with non-wild-type susceptibility had the following substitutions in
CYP51A: M220I (isolate V28-77), G54W (isolate V59-73), and TR/L98H (iso-
late V52-35). A clinical isolate without substitutions in CYP51A was used as a
wild-type control (AZN8196). For all isolates, the cyp51A substitutions and strain
identification were confirmed by sequence-based analysis as described previously
(Table 1) (20). In addition, microsatellite typing of the four isolates by short
tandem repeat typing was performed to confirm that they were genetically dis-
tinct (20). The isolates had been stored in 10% glycerol broth at80°C and were
revived by subculturing on Sabouraud dextrose agar (SDA) supplemented with
0.02% chloramphenicol for 5 to 7 days at 35°C.
Susceptibility testing was performed based on the M38A method of the Clin-
ical and Laboratory Standards Institute (CLSI), using a broth microdilution
format (15).
Infection model. A total of 143 outbred CD-1 (Harlan, Horst, Netherlands)
female mice (20 to 25 g; 4 to 5 weeks old) were randomized into 13 groups (n 
11 per group) for the four different A. fumigatus strains. Before the experiment,
the isolates were cultured once on SDA for 7 days at 35°C and subcultured twice
on Takashio slants (15-cm slants) for 5 days at 35°C. The conidia were harvested
in 20 ml of sterile phosphate-buffered saline (PBS) plus 0.1% Tween 80 (Boom
B.V., Meppel, Netherlands). The conidial suspension was filtered through sterile
gauze folded four times to remove any hyphae, and the number of conidia was
counted in a hemacytometer. After the inoculum was adjusted to the required
concentration, the conidial suspension was stored overnight at 4°C.
Mice were infected via injection in the lateral tail vein with an inoculum
corresponding to the 10% survival dose of each isolate, as determined before
(11). Postinfection viability counts of the injected inocula were determined to
ensure that the correct inoculum had been injected. Therapy was begun 24 h
after infection and continued for 14 days. Voriconazole (Pfizer, Capelle a/d
IJssel, Netherlands) oral solution was administered in doses of 10, 40, and 80
mg/kg of body weight by oral gavage once daily. The placebo groups were
infected with one of the aforementioned isolates and received single doses of
saline by oral gavage. On day 15 postinfection, all remaining mice were eutha-
nized humanely under isoflurane anesthesia.
The animals were housed under standard conditions, with drink and feed
supplied ad libitum. The animal studies were conducted in accordance with the
recommendations of the European community (directive 86/609/EEC, 24 No-
vember 1986), and all animal procedures were approved by the Animal Welfare
Committee of Radboud University (procedures RU-DEC 2007-30 and RU-DEC
2008-105).
The infected mice were examined at least three times daily. Clinical inspec-
tions were carried out in order to ensure that there were no cases of desiccation,
torticollis, staggering, rapid weight loss (15% decrease within 48 h or 20%
decrease within 24 h), or body temperature drop to below 33°C. Mice demon-
strating these signs of disease were terminated humanely.
Pharmacokinetic analysis. A total of 72 outbred CD-1 (Charles River, Neth-
erlands) female mice (20 to 22 g; 4 to 5 weeks old) were used for separate
pharmacokinetic experiments. On day 0, mice were infected with the wild-type A.
fumigatus isolate through the lateral tail vein, and after 24 h, treatment was
initiated as described above, with a dosage of 10, 40, or 80 mg/kg. On day 2 of
voriconazole treatment (day 3 after infection), blood samples were drawn from
the orbital vein into lithium-heparin-containing tubes at 8 predefined time
points: immediately before administration of voriconazole and at 0, 0.5, 1, 2, 4,
6, 9, and 24 h postdosing. Blood samples were centrifuged for approximately 10
min at 1,000  g within 30 min of collection. Plasma was aspirated, transferred
to two 5-ml plastic tubes, and stored at 70°C. Total and unbound voriconazole
samples were measured by a validated (for human and mouse matrices) high-
performance liquid chromatography (HPLC) method with fluorescence detec-
tion (Thermo Scientific, Breda, Netherlands), using a SymmetryShield RP18
column (Waters, Ettenleur, Netherlands). Samples were pretreated using a pro-
tein precipitation procedure. The dynamic range of the assay was 0.05 to 10
mg/liter. The assay had an accuracy range (n  15), depending on the concen-
tration, of 96.7% to 101.4%. Intraday precision varied between 0.8% and 3.2%,
and interday precision was between 0 and 2.0%. To determine the free fraction
of voriconazole, we pooled plasmas from identical time points (n 3 samples per
time point; time points were 1, 2, and 4 h after oral gavage) for all three dosing
regimens to obtain at least 0.5 ml voriconazole-containing plasma. The recovery
from mouse plasma of the ultrafiltrate was 83.1% (standard deviation [SD],
3.2%). No loss of voriconazole to the filter occurred during ultrafiltration. The
plasma was then transferred to YM-30 Centrifree centrifuge tubes (Millipore,
Carrigtwohill, Ireland). Samples were centrifuged for 10 min at a relative cen-
trifugal force (RCF) of 2,000 (3,310 rpm) (Rotante 46R centrifuge with radius of
164 mm and angle of 45°; temperature, 25°C). The ultrafiltrate was injected
directly onto the HPLC system. For very low concentrations, the method was
slightly modified to obtain a lower limit of quantitation, 0.01 mg/liter, without a
loss of accuracy and precision. The assay was validated for mouse plasma and was
validated externally by an international proficiency testing program (4).
Arithmetic mean plasma concentrations for three mice per time point were
calculated. Peak plasma concentrations (Cmax) were observed directly from the
data. Pharmacokinetic parameters were derived using noncompartmental anal-
ysis with WinNonLin 5.2 (Pharsight Inc., Mountain View, CA). The area under
the plasma concentration-time curve from time zero to 24 h postinfusion (AUC0–24)
was determined by use of the log-linear trapezoidal rule. The elimination rate
constant was determined by linear regression of the terminal points of the
log-linear plasma concentration-time curve. The terminal half-life was defined as
the ln2 divided by the elimination rate constant. Clearance (CL) was calculated
as dose divided by AUC0–24.
Statistical analysis. All data analyses were performed by using the software
package GraphPad Prism, version 5.0, for Windows (GraphPad Software, San
Diego, CA). A regression analysis was conducted to determine linearity between
dose and AUC. Mortality data were analyzed by the log rank test. The survival
data were plotted against the dose/MIC ratio, and the Hill equation with variable
slope was fitted to the data, both for each individual strain and for pooled
survival data. The goodness of fit was checked by determination of the R2 value
and visual inspection. Moreover, the Emax (Hill) model was used to evaluate the
exposure index for free drug (fEI) required for 20% (fEI20), 50% (fEI50), 80%
(fEI80), and 90% (fEI90) of maximum effectiveness and outcome for all isolates.
Statistical significance was defined as a P value of 0.05 (two-tailed). Dose/
MIC, AUC/MIC, and fAUC/MIC ratios were calculated by dividing the dose
TABLE 1. Origins, in vitro susceptibilities, and underlying azole resistance mechanisms of A. fumigatus isolates
Isolate Origin Prior azoleexposure
Cyp51A
substitution
MIC (mg/liter)a
AMB ITZ VCZ POS CAS
AZN 8196 Proven invasive aspergillosis No 0.5 0.125 0.25 0.031 0.25
V28-77 Aspergilloma ITZ M220I 0.5 16 0.25 0.5 0.25
V59-73 Clinical, disease entity unknown Unknown G54W 0.5 16 0.125 16 0.25
V52-35 Proven invasive aspergillosis (24) No TR/L98H 0.5 16 2 0.5 0.25
a AMB, amphotericin B; ITZ, itraconazole; VCZ, voriconazole; POS, posaconazole; CAS, caspofungin. For caspofungin, the minimum effective concentration was
determined.
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(mg/kg of body weight), AUC, or AUC for the free, unbound fraction of the drug
(fAUC) by the MIC. Dose/MIC, AUC/MIC, and fAUC/MIC ratio data were
transformed to log10 values to approximate a normal distribution prior to sta-
tistical analysis.
RESULTS
In vitro activity. The in vitro susceptibility profiles of the four
isolates are presented in Table 1. Voriconazole showed re-
duced in vitro activity against the TR/L98H isolates, with a
MIC of 2 mg/liter. The G54W isolate was resistant to itracon-
azole and posaconazole, and the M220I isolate was resistant to
itraconazole. However, the MICs of voriconazole for these
isolates were 0.125 mg/liter and 0.25 mg/liter, respectively.
These MIC values are comparable to that of the wild-type
control isolate.
Survival curves. The survival curves for all 4 control groups
receiving saline by oral gavage showed a mortality rate of 90 or
100% and a median survival time of 2 to 3 days. Figure 1 shows
the survival curves for the 4 infection groups against time. The
survival study indicated that for all 4 groups, the outcome was
significantly improved when the voriconazole concentration
increased from 10 to 40 mg/kg or from 40 to 80 mg/kg (P 
0.0001). A comparative analysis of the 10-mg/kg dose of vori-
conazole between groups showed no difference in survival be-
tween all four groups (log rank test; P  0.37). For the dose of
40 mg/kg, the comparative analysis showed no significant dif-
ference in survival for the wild-type and M220I and G54W
mutant groups (P  0.22). In contrast, mice infected with the
TR/L98H mutant showed a significant difference in therapeu-
tic response compared to the 3 other isolates (P  0.0007): a
2-fold increase of voriconazole dosage was required for mice
infected with the TR/L98H isolate to achieve a maximum re-
sponse similar to that obtained with the wild-type isolate.
Pharmacokinetic analysis. Table 2 shows the results of the
pharmacokinetic experiments. A total of 72 mice (3 mice per
time point, 8 time points, 3 different dosages) were available
for pharmacokinetic assessment. All 72 mice were alive at the
time of sample collection. The AUC normalized to a dose of 10
mg/kg resulted in ratios of 0.31, 1.75, and 3.68 for dosages of
10, 40, and 80 mg/kg, respectively. Clearance decreased with
increasing doses, showing nonlinearity.
Plasma voriconazole concentrations after administration of
oral doses of 10, 40, and 80 mg/kg are shown in Fig. 2. The
unbound fractions of voriconazole in the three different dosing
FIG. 1. Efficacy of voriconazole monotherapy at 10, 40 (all isolates), and 80 (TR/L98H isolate) mg/kg, depicted by strain. Placebo groups received
saline. For all groups, n  11.
TABLE 2. Pharmacokinetic parameters of voriconazole after doses of 10 to 80 mg/kg by oral gavage
Treatment dose
(mg/kg)
AUC
(h  mg/liter)
Dose-normalized
AUC (mg  h/
liter  kg)
fAUC
(mg  h/liter  kg)
CLss/F
(liters/h  kg)
Cmin
(mg/liter) Cmax (mg/liter) Tmax (h) t1/2 (h)
10 3.05 0.31 0.911 2.53 0.36 1.61 0.5 1.75
40 70.12 1.75 20.94 0.39 4.58 11.81 2.0 5.01
80 294.61 3.68 88.00 0.10 23.01 35.86 2.0 16.21
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arms (n  3 per dosing arm) were 26.51%, 33.28%, and
30.59% for the 10-, 40-, and 80-mg/kg groups, respectively. The
geometric mean unbound voriconazole fraction for all groups
combined (n  9) was 29.97% (95% confidence interval [95%
CI], 27.56 to 32.59%). No comparison between the dosing
regimens was performed because the numbers were too small
to perform a valid statistical analysis and draw firm conclu-
sions. These data indicate that there was no concentration-
dependent protein binding over the range measured. There
was no significant loss of voriconazole in the filter system.
Dose-response analysis. The dose-response curves for the
four voriconazole dosing regimens and controls for all four
strains are shown in Fig. 3 for days 7 and 14. Voriconazole
treatment improved the survival of the mice in a dose-depen-
dent manner for all four isolates. The curve for the TR/L98H
mutant was shifted to the right because this isolate had a
higher MIC than the other three isolates, and thus a higher
dose was required to obtain a similar efficacy (100% survival).
Dose/MIC ratio-survival plots for days 7 and 14 for all four
strains are depicted in Fig. 4. As can be observed, there was
significant scatter around the line of best fit by the Hill model
(R2 values of 0.60 and 0.54, respectively) for days 7 and 14.
Since voriconazole displays nonlinear pharmacokinetics, this
could be the reason for the observed scatter. The 50% effective
dose (ED50) for day 7 was 42.82 mg/kg, and that for day 14 was
59.84 mg/kg.
Exposure-response analysis. The AUC and fAUC for each
dose, as determined from the pharmacokinetic experiments,
were used to calculate the AUC0–24/MIC and fAUC0–24/
MIC ratios for each strain. The relationships between expo-
sure and response on days 7 and 14 for all groups are shown
in Fig. 5 and 6 (AUC0–24/MIC and fAUC/MIC ratios, re-
spectively).
The relationships of AUC/MIC and fAUC/MIC ratios with
response were significantly better for both time points (R2
values of 0.96 and 0.98) than for the dose/MIC ratio (R2 values
of 0.60 and 0.54), as expected for a drug with nonlinear clear-
ance. The estimates of the fEI50s on day 7 were similar to those
obtained on day 14 (11.2 and 10.5, respectively) (Fig. 6), but
the Hill slope was much steeper on day 14. The confidence
intervals on day 14 for both the Hill slope and the EI50 were
relatively wide, despite the high R2 values and seemingly good
fit. Inspection of goodness-of-fit criteria indicated that the co-
variance between these two parameters was very high, mainly
because only one data point was present above 10% and below
100% survival, resulting in large standard errors (SE).
DISCUSSION
Our animal model indicated that the efficacy of voriconazole
was significantly reduced in mice infected with the TR/L98H
isolate, which had a MIC of 2 mg/liter. According to recently
proposed breakpoints, a MIC of 2 mg/liter should be inter-
preted as intermediate susceptibility (26). In a previous study,
we investigated the efficacy of posaconazole against the same
four clinical A. fumigatus isolates as those used in our present
study (11). The posaconazole MICs ranged from 0.063 to 16
mg/liter, and we showed that the MIC had a major impact on
posaconazole efficacy (11). Our model indicated that for vori-
conazole, the MIC had a major impact as well, and a significant
dose increase was required in mice infected with the TR/L98H
isolate (MIC of 2 mg/liter) to achieve a similar voriconazole
efficacy to that in mice infected with a wild-type isolate (MIC
of 0.25 mg/liter). Because of the nonlinear pharmacokinetics of
voriconazole (see below), the dose required to obtain a similar
effect was only twofold higher for the TR/L98H mutant-in-
fected animals.
The exposure-response relationship of voriconazole indi-
cated that improvement of survival for all four clinical isolates
was dependent on the voriconazole dose, but a much better
relationship existed with the total AUC/MIC or fAUC/MIC
ratio. The significantly improved fAUC/MIC relationship, as
opposed to the dose/MIC relationship, can be explained by the
FIG. 2. Plasma voriconazole concentrations after administration of
oral doses of 10, 40, and 80 mg/kg to immunocompetent infected mice.
Each symbol corresponds to the geometric mean standard deviation of
plasma levels for three mice.
FIG. 3. Voriconazole dose-survival relationships for four A. fumigatus isolates. Voriconazole treatment improved the survival of the infected
mice in a dose-dependent manner for all four isolates. The curves indicate fits with the Hill equation for each isolate.
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nonlinear clearance of voriconazole. Thus, as opposed to
posaconazole, the effect of voriconazole cannot readily be pre-
dicted by dose alone.
Our animal model furthermore showed that voriconazole
remained effective against isolates with a MIC that was within
the wild-type range despite the presence of a Cyp mutation and
high MICs of other triazoles (26). The efficacy of voriconazole
against these isolates was similar to that of the wild-type iso-
late. We recently investigated the relationship between Cyp
mutations and the Cyp51A protein by using a homology model
(2). This model indicated that there are two ligand access
channels which are probably used by azole compounds for
docking. Amino acids G54 and M220 are located in loops in
close proximity to the opening of channel 2. It was suggested
that changes close to the entrance of channel 2 disturb the
docking of large azole molecules, such as itraconazole and
posaconazole. Voriconazole, however, is a much smaller mol-
ecule and can access channel 2 or even channel 1 of the G54W
and M220I mutants in modeling experiments (Fig. 7B and C),
which corresponds with the MIC being similar to that of a
wild-type isolate. In contrast, the change of leucine to histidine
in the L98H mutant can disturb both channels 1 and 2 through
a change at position Y107 (Fig. 7A), resulting in attenuated
voriconazole susceptibility. The protein model therefore sup-
ports our observed phenotypes in vitro and the efficacy of
voriconazole in vivo. Our aspergillosis model suggests that pa-
tients with an infection due to an A. fumigatus isolate that is
resistant to one or more azoles but susceptible to voriconazole
could be treated with this azole.
Voriconazole exposure-response relationships have been in-
vestigated in different experimental models of fungal infec-
tions. These studies seemed to suggest that the mouse is a poor
model for investigating the efficacy of voriconazole in vivo
because of the rapid elimination of the drug, whereas guinea
pigs, with their slower metabolism and clearance, are able to
retain the drug in their system longer (9, 19, 21). However,
mice are preferred over guinea pigs for efficacy studies because
they offer advantages in cost, animal handling, and housing. To
improve the murine model for study of voriconazole, the use of
grapefruit juice has been adopted by some authors for its
property of inhibiting intestinal CYP3A4 and, as a conse-
quence, enhancing systemic exposure (25). However, the use of
grapefruit juice has several disadvantages. The first is a lack of
standardization of the contents of the juice. The second is
possible yet unknown interactions of grapefruit juice with vori-
conazole metabolism and activity. Furthermore, Graybill et al.
suggested that grapefruit juice may exhibit antifungal activity
or inhibit fungal cytochrome enzymes (7). Given that there are
not sufficient data about the effects of the juice on the intrinsic
factors of the CYP genes of the fungus or even the host im-
mune system, we employed the experimental mouse model
without grapefruit juice application. By carrying out a timed
FIG. 4. Survival as a function of voriconazole dose/MIC ratio for mice infected with four A. fumigatus isolates at two different time points. In
mice infected with the TR/L98H isolate (MIC of 2 mg/liter), doubling of the dose to 80 mg/kg was required in order to achieve a similar outcome
(100%) to that for the groups infected with a wild-type isolate (MIC of 0.25 mg/liter). The curve is the model fit with the Hill equation for pooled
data.
FIG. 5. Statistical timed analysis of survival as a function of voriconazole AUC/MIC ratio for four A. fumigatus isolates. Increased voriconazole
exposure was required to obtain maximum efficacy in mice infected by isolates with attenuated susceptibility. The curve is the model fit with the
Hill equation for pooled data.
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analysis of the exposure-response data, we were able to deter-
mine the relationship between these two factors, confirming
that these parameters can be investigated in a grapefruit juice-
free model.
Besides rapid clearance of voriconazole, another potential
drawback of the mouse model is the decrease of systemic
exposure of voriconazole during multiple dosing experiments,
probably due to autoinduction of voriconazole metabolism
(19). This phenomenon is more pronounced in mice and rats
than in guinea pigs (19). We found that the pharmacodynamic
analysis could be performed on day 7 of the study, which
reduces the impact of autoinduction and reduces animal suf-
fering. Although we did not measure the voriconazole expo-
sure on day 14, the survival-AUC/MIC relationships were sim-
ilar for both time points in that the EI50 values were similar.
However, the Hill slope was steeper on day 14. This effect
could be due to the autoinduction phenomenon because of the
lower voriconazole plasma levels on day 14 than on day 7. This
phenomenon would result in lower drug exposure, and there-
fore a lower percent survival, on day 14 than on day 7, as shown
in Fig. 5. However, the confidence interval for the EI50 estimate
was large, mainly because only one data point was present above
10% and below 100% survival, resulting in large SE.
Statistical analysis at two time points of therapy demon-
strated that the fAUC/MIC ratio is the critical pharmacoki-
netic-pharmacodynamic index associated with treatment effi-
cacy of voriconazole against aspergillosis. As early as day 7, as
depicted in Fig. 6, the 24-h fAUC/MIC ratio showed a clear
relationship to effect, and a maximum effect was reached at
values of around 80 to 100. This corresponds to values found
for Candida infections (1, 18) and for Gram-negative micro-
organisms (6). This indicates that our model is robust and
useful for investigating clinically relevant pharmacokinetic and
pharmacodynamic relationships, despite the fact that it is a
nonneutropenic model and that infection is established
through intravenous inoculation of mice rather than following
the natural route of infection, via the airways. It also corre-
sponds with a 2-log reduction of CFU of Candida after 2 h, as
described by Andes et al. (1). For most triazoles, effect is
governed only by the concentration of free drug (1, 5). Our
aspergillosis model showed a voriconazole protein-free frac-
tion of 29.87% (standard deviation, 2.9%). This was similar for
all doses and for three different time points. Previous studies of
humans showed that standard-dose oral voriconazole results in
a total AUC0–24 value of 18 to 23 mg  h/liter (17). An oral
dose of 200 mg twice daily would result in a free drug AUC of
8.4 g  h/ml (16). For hematopoietic stem cell transplant
(HSCT) recipients, the median total AUC0–24 was found to be
approximately 70 mg  h/liter on study day 7 and 50 mg  h/liter
on day 14 (3), which would correspond to an fAUC of approx-
FIG. 6. Survival as a function of fAUC/MIC ratio for four A. fumigatus isolates. Based on the voriconazole exposure data after oral
administration of 10, 40, and 80 mg/kg, an fAUC/MIC ratio of 80 to 100 might protect against azole-resistant A. fumigatus species with MICs
reaching 2 mg/liter. The curve is the model fit with the Hill equation for pooled data.
FIG. 7. Channels 1 and 2 of the G54W and M220I -demethylase mutants are accessible for voriconazole (B and C), whereas they are closed
through a position change of Y107 by the L98H mutation (A). The two ligand access channels are indicated in green. The heme cofactor is
indicated in black.
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imately 21 and 15 mg  h/liter, respectively, based on a free
fraction of 29.87%. A previous study (1) reported a voricon-
azole protein binding level of 78%. The reasons for these
discrepant findings include possible experimental variation,
use of other animals, or use of different methods of determin-
ing protein binding.
Our model indicates that the highest MIC at which infec-
tions can be treated with maximum efficacy is 0.25 mg/liter. In
our opinion, taking the variation in pharmacokinetic parame-
ters in the population into account, as determined by Monte
Carlo simulations (EUCAST voriconazole rationale docu-
ment, version 2.0 [www.eucast.org]), the MIC would be even
lower, i.e., 0.125 mg/liter, which is similar to the EUCAST
breakpoint for Candida spp.
We concluded that our model supports the view that the
efficacy of voriconazole treatment against A. fumigatus is de-
pendent both on drug exposure and on the MIC for the isolate,
like the case for other antifungal drugs (11). Although vori-
conazole has a nonlinear pharmacokinetic profile, the quanti-
tative relationship between exposure and effect was compara-
ble to that found for posaconazole. We have shown that
increased voriconazole exposure is required to obtain maxi-
mum efficacy in mice infected by isolates with attenuated sus-
ceptibility, while the drug remains effective against those iso-
lates with high MICs for other azoles but MICs for
voriconazole that are within the wild-type population range.
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